Aravive, Inc., a clinical stage biotechnology company, focuses on developing therapies for solid tumors and hematologic malignancies. Its lead candidate is AVB-S6-500, a soluble Fc-fusion protein, which is in Phase 1b/2 clinical trials for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, acute myeloid leukemia, triple negative breast cancer, and pancreatic cancer. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. is headquartered in Houston, Texas.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone936-355-1910
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.37 million
Profitability
Miscellaneous
Employees14
Next Earnings Date3/5/2020 (Estimated)
OptionableOptionable
Aravive (NASDAQ:ARAV) Frequently Asked Questions
What is Aravive's stock symbol?
Aravive trades on the NASDAQ under the ticker symbol "ARAV."
How were Aravive's earnings last quarter?
Aravive Inc (NASDAQ:ARAV) announced its quarterly earnings data on Thursday, November, 7th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.50) by $0.04. View Aravive's Earnings History.
When is Aravive's next earnings date?
What price target have analysts set for ARAV?
5 equities research analysts have issued 1 year price targets for Aravive's stock. Their forecasts range from $25.00 to $31.00. On average, they anticipate Aravive's share price to reach $28.50 in the next twelve months. This suggests a possible upside of 225.3% from the stock's current price. View Analyst Price Targets for Aravive.
What is the consensus analysts' recommendation for Aravive?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aravive in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aravive.
Has Aravive been receiving favorable news coverage?
Press coverage about ARAV stock has been trending very negative recently, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Aravive earned a news impact score of -3.7 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Aravive.
Are investors shorting Aravive?
Aravive saw a increase in short interest in the month of February. As of February 14th, there was short interest totalling 322,200 shares, an increase of 231.5% from the January 30th total of 97,200 shares. Based on an average daily volume of 528,500 shares, the days-to-cover ratio is presently 0.6 days. Currently, 3.8% of the shares of the stock are short sold. View Aravive's Current Options Chain.
Who are some of Aravive's key competitors?
Some companies that are related to Aravive include Crinetics Pharmaceuticals (CRNX), Kura Oncology (KURA), XBiotech (XBIT), Endonovo Therapeutics (ENDV), Assembly Biosciences (ASMB), Neoleukin Therapeutics (NLTX), Milestone Pharmaceuticals (MIST), AC Immune (ACIU), CytoDyn (CYDY), Prothena (PRTA), Magenta Therapeutics (MGTA), Viking Therapeutics (VKTX), Sinovac Biotech (SVA), Morphic (MORF) and TherapeuticsMD (TXMD).
What other stocks do shareholders of Aravive own?
Who are Aravive's key executives?
Aravive's management team includes the folowing people:
- Mr. Jay P. Shepard, Pres, CEO & Director (Age 61)
- Dr. Jeffrey L. Cleland, Co-Founder (Age 54)
- Dr. Joshua Silverman Ph.D., Co-Founder
- Mr. Vinay Shah, Chief Financial Officer
- Dr. Gail F. McIntyre, Chief Scientific Officer (Age 56)
Who are Aravive's major shareholders?
Aravive's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include New Leaf Venture Partners L.L.C. (6.46%), FMR LLC (4.77%), Samsara BioCapital LLC (3.93%), Renaissance Technologies LLC (2.19%), Alpine Global Management LLC (0.69%) and UBS Group AG (0.56%). Company insiders that own Aravive stock include Jay Shepard, Kevin Haas and Srinivas Akkaraju. View Institutional Ownership Trends for Aravive.
Which major investors are selling Aravive stock?
Which major investors are buying Aravive stock?
ARAV stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Renaissance Technologies LLC, Samsara BioCapital LLC, Alpine Global Management LLC, Bank of Montreal Can, EAM Investors LLC, Schonfeld Strategic Advisors LLC and Geode Capital Management LLC. View Insider Buying and Selling for Aravive.
How do I buy shares of Aravive?
Shares of ARAV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Aravive's stock price today?
One share of ARAV stock can currently be purchased for approximately $8.76.
How big of a company is Aravive?
Aravive has a market capitalization of $128.33 million and generates $1.37 million in revenue each year. The company earns $-76,330,000.00 in net income (profit) each year or ($10.64) on an earnings per share basis. Aravive employs 14 workers across the globe.View Additional Information About Aravive.
What is Aravive's official website?
How can I contact Aravive?
Aravive's mailing address is River Oaks Tower3730 Kirby Drive Suite 1200, Houston TX, 77098. The company can be reached via phone at 936-355-1910 or via email at [email protected]
MarketBeat Community Rating for Aravive (NASDAQ ARAV)
MarketBeat's community ratings are surveys of what our community members think about Aravive and other stocks. Vote "Outperform" if you believe ARAV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARAV will underperform the S&P 500 over the long term. You may vote once every thirty days.
